Veeva’s mission-critical life-sciences cloud franchise pairs a deep regulatory moat and 44.5% guided operating margins with Vault CRM, R&D expansion, and AI upside, though migration execution and a premium valuation temper returns.
Overview
Veeva Systems is the dominant vertical-cloud software and data provider focused on life sciences, with customers spanning virtually all top 50 global pharmaceutical companies and hundreds of emerging biotechs. Subscription SaaS licenses account for approximately 83% of revenue, complemented by roughly 17% professional services; its Vault platform serves commercial, clinical, regulatory, quality, and safety workflows. Compliance requirements, validated systems, and cross-functional data integration create high switching costs and a differentiated position against horizontal vendors. In Q2 FY2027, revenue rose 17.6% to $928.0 million, subscription revenue increased 16.3% to $766.8 million, and non-GAAP EPS of $2.35 beat consensus of $2.10. Management raised FY2027 revenue guidance to $3,682–$3,687 million and non-GAAP EPS to approximately $9.21, implying about a 44.5% non-GAAP operating margin. **Vault CRM migration and R&D expansion underpin continued growth**, while Falcon AI agents could extend the platform’s value proposition. At $295.85, shares trade at roughly 32.0x forward non-GAAP P/E and 10.6–11.8x EV/Sales, a premium justified by recurring revenue and >40% FCF margins but demanding execution. The five-year probability-weighted target is $467.93, with CRM deployment and AI adoption as near-term catalysts.